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Summary
Prothymosin alpha (PTMA), a nuclear oncoprotein involved in cell cycle regulation, is used as 
a prognostic marker in many cancers. The histopathology of pituitary carcinomas and locally 
invasive adenomas is indistinguishable from that of benign tumors. A new marker is needed 
to differentiate these lesions. We evaluated PTMA in pituitary adenomas to determine its 
usefulness as a prognostic factor of tumor proliferation. 
We conducted a retrospective analysis of a group of 27 patients, including 15 females (56%) 
and 12 males (44%) with a mean age of 58.6±12 years, who underwent pituitary tumor surgery 
between 2003 and 2012. The Ki-67 and PTMA-nuclear (PTMA-n) and PTMA-cytoplasmic (PTMA-
-c) indices were determined by immunohistochemical staining. We studied histopathological 
features, clinical symptoms, and magnetic resonance imaging or computed tomography per-
formed before surgery and one year following surgery to evaluate tumor size and progression. 
The expression of Ki-67 was revealed in 77.8% of adenomas, PTMA-n in 81.5% and PTMA-c in 
92.6%. The mean value of the Ki-67 index was 1.8%, PTMA-n was 1.84%, and PTMA-c was 35.6%. 
There was a significant positive correlation between Ki-67 and PTMA-n (p=0.009). We did not 
find any correlation between Ki-67, PTMA-c, and tumor progression. PTMA-n was found to be 
correlated with tumor size (p=0.045) and was higher in the case of gonadotropinomas (p=0.026).
The positive nuclear expression of Ki-67 and PTMA was observed in the majority of pituitary 
adenomas. Neither the expression of Ki-67 nor that of PTMA-c was related to tumor recur-
rence or local invasion.
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IntroductIon
In the majority of cases of benign adenomas, pituitary 
tumors are very rare (0.02% of the population) [14]. They 
are divided by size into microadenomas (<1  cm) and 
macroadenomas (≥1 cm) [14]. 
According to the 2004 WHO classification, pituitary ade-
nomas are typical, atypical, and cancerous [14,16]. Eleva-
ted invasiveness, mitotic index, nuclear staining for p53, 
and Ki-67 labeling index >3% suggest aggressive beha-
vior [19]. However, brain invasion is not accepted as the 
only criterion.
Clinical symptoms such as hormonal activity or symp-
toms associated with the “mass effect” and the invasion 
of surrounding tissues (supra-sellar extension, sinus 
cavernous invasion, and optic chiasm compression) 
may occur [3]. Many pituitary adenomas (3.7-20%) are 
incidentally detected by computed tomography (CT) 
or magnetic resonance imaging (MRI) performed for 
unrelated reasons; they are also incidentally detected in 
about 10% of postmortem examinations [14].
Based on physical examinations and blood hormone 
levels, pituitary tumors can be divided into functioning 
(FPA) and non-functioning (NFPA) [14]. The predicted 
hormonal activity of a tumor is not always confirmed 
by postoperative immunohistological examination. 
According to the histopathological expression of speci-
fic pituitary hormones, adenomas are divided into the 
Pit-1 family (prolactinoma, PRL secretion: 50%; somato-
tropinoma, GH secretion: 15-20%; thyrotropinoma, TSH 
secretion: 1%; plurihormonal adenoma), ACTH family 
(corticotropinoma: 5-10%), gonadotropin family (gona-
dotropinoma, LH, FSH secretion: 1%) and unclassified 
adenomas (hormone negative/null cell adenomas, NCA 
(30%) and unusual plurihormonal adenomas) [1,3,10]. 
Pituitary carcinomas (0.1-0.2% of all cases of pituitary 
tumors) are diagnosed if metastasis is observed; their 
prognosis is very poor [14,19]. Therapy for large invasive 
tumors with post-surgery re-growth, persistent hormo-
nal function despite near total resection, or pituitary 
carcinomas is challenging and includes, besides surgery 
and pharmacological treatment, radiotherapy and temo-
zolomide [10]. In these cases, adjusted therapy and pro-
per periodic monitoring are crucial.
Pituitary adenomas classified according to WHO guide-
lines do not always correlate with clinical prognoses 
[19]. Many are invasive (30-45%), and some are clinically 
aggressive [19]. The WHO 2004 classification of pituitary 
adenomas does not include the term invasive and non-
-invasive adenoma. This aspect of the WHO classifica-
tion has been criticized many times, and a need for the 
reexamination of the criteria of malignancy was repor-
ted [1,10,19,21]. Therefore, some authors divide adeno-
mas into particular groups: non-invasive, non-invasive 
and proliferative, invasive +/- proliferative, and meta-
static [8,19]. Some have suggested naming atypical ade-
nomas carcinoma in situ or premetastatic cancer [11].
There are no defined histological criteria dividing benign 
and malignant tumors, and especially for distinguishing 
atypical adenoma from pituitary adenocarcinoma. Mar-
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The surgical specimens were routinely processed, fixed 
in neutral buffered formalin, embedded in paraffin, and 
slided. Sections were incubated, inter alia, in the pri-
mary mouse monoclonal antibody Ki-67 clone MIB-1 
antibody (Dako, M7240, 1:25) in the case of Ki-67, and 
in the primary monoclonal rabbit antibody prothymo-
sin alpha (Acris-Antibodies GmbH, 1:1000) in the case 
of prothymosin alpha. In all cases, an evaluation of the 
Ki-67 and PTMA labeling index of the surgical specimens 
was performed using the antibody. To confirm the spe-
cificity of the primary antibody, positive and negative 
control tests were performed following the manufactu-
rers’ instructions.
Ki67 and PTMA-stained sections were evaluated by 
manual counting using an optical microscope (Nikon 
Optishot-2). Ten fields were selected in regions with the 
highest concentration of positive nuclei and were exa-
mined at a high power magnification (400x). Each field 
comprised 700 to 3800 cells in relation to the cellularity 
of the tumor specimen. The Ki-67 and PTMA-n indices 
were defined as the percentage of positive stained nuc-
lei, and PTMA-c was defined as the percentage of posi-
tive cytoplasm (see photos in figure 1a, 1b, 1c).
Statistical analysis was performed using the R statistical 
package. Analysis of variance, Student’s t-test, Pearson’s 
r correlation, Wilcoxon text, and Spearman’s rho corre-
lation were performed.
results
The results of a retrospective and basic immunohisto-
chemical analysis of the group are shown in Table 1.
The occurrence of hormone immunopositive expression 
was established in 17 (63%) cases. In some adenomas, 
the expression of more than one hormone was found. 
All studied groups consisted of macroadenomas. 
KI-67, PtMA-n, And PtMA-c
Results concerning the expression of Ki-67, PTMA-n, and 
PTMA-c are shown in Table 2.
The PTMA-n expression correlated with Ki-67 (p=0.009), 
as presented in Figure 2. 
There was no significant difference between PTMA-n, 
PTMA-c, and Ki-67 based on age or gender. 
ProgressIon
Progression of the tumor within 12 months of the obser-
vation occurred in 6 cases (22%). We did not find any sig-
nificant difference between Ki-67 or PTMA-c indices and 
tumor progression (p=0.8 in both). 
However, the mean PTMA-n expression was significantly 
lower in the subpopulation with a tumor that progressed 
kers are needed that can consistently correlate with 
biological tumor behavior. Such potential indicators of 
tumor behavior are markers of proliferation and angio-
genesis. Besides the documented Ki-67 (MIB-1 antibody), 
topoisomerase II alpha, COX-2, and Bcl-2 were studied 
[16,18]. However, they have not yet shown consistent 
correlation with tumor invasiveness or recurrence [1]. 
PPTG (pituitary tumor transforming gene), VEGF, pro-
thymosin alpha (PTMA), and AIP are new promising bio-
logical tumor behavior markers. 
Ki-67 is a nuclear antigen expressed in phase G1, S, G2, 
and M of the cell cycle and recognized by the commer-
cially available antibody MIB-1 [2,7]. The Ki-67 labeling 
indices can vary from <1% to 23% in a series [15]. PTMA 
is an oncoprotein that is a product of the 2q37.1 gene 
and is present in nuclei or cytoplasm. It is involved in 
proliferation and protection against apoptosis; its ove-
rexpression has been found in cancers of the head and 
neck, lungs, kidney, bladder, and breast [4,6,19].
The aim of this study was to:
• determine the usefulness of PTMA as a prognostic fac-
tor of the recurrence of pituitary adenoma;
• evaluate the relationship between the proliferative 
activity of pituitary adenomas, quantified by Ki-67 and 
PTMA indices, and their aggressive biology and clinical 
data;
• investigate the correlation between the PTMA labeling 
index and tumor size and local invasion.
MAterIAl And Methods
Our study was a retrospective analysis of the clinical 
records and histopathological and immunohistochemi-
cal preparations of the pituitary adenomas of 27 patients 
of the Clinical Department of Endocrinology at the Uni-
versity Hospital in Cracow who underwent a trans-
sphenoidal resection of the pituitary adenoma and/or 
craniotomy in the Clinical Department of Neurosurgery 
at the University Hospital in Cracow between 2003 and 
2012. The diagnosis was established by clinical, bioche-
mical, and radiological findings and was confirmed by 
surgery and a histopathological survey. 
MRI or CT was performed before surgery and one year 
after surgery for all patients to determine potential 
tumor progression. Tumor size, defined as its largest 
dimension, and relation to neighboring tissues (sella 
turcica destruction, penetration into sinus cavernous, 
optic chiasm compression, suprasellar propagation) 
were studied using MRI/CT. Tumor invasiveness was 
defined by radiological criteria [5,20] and from the sur-
geon’s description found in patients’ medical records. 
Tumor progression was defined as evidence of recur-
rence or increase of the remnant tumor in MRI/CT after 
one year of observation following surgery.
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Fig. 1a. The strong, mainly cytoplasmatic, reaction to 
PTMA antibody, 400x magnification
Fig. 1b. Strong immunopositive cytoplasmatic 
reaction to PTMA antibody in one cell, 600x 
magnification
Fig. 1c. Several cells with mixed cytoplasmatic 
and nuclear reaction to PTMA antibody, 600x 
magnification
Table 1. Patients characteristics (n=27).
General data
Age [years]: mean/median  (min.-max.) 58.6 / 61 (29 - 80)
Gender: Female/Male 15 (55.5%) / 12 (44.5%)
Imaging results
Largest dimension of tumor [mm] 45
Minimal dimension of tumor [mm] 10
Microadenoma / Macroadenoma 0 (0%) / 27 (100%)
Optic chiasm compression 17 (63%)
Local invasion of tumor 25 (92.6%)
Final clinical classification
of pituitary adenomas
in patient group
Clinically non-functioning adenoma (NFPA) 20 (74%)
Prolactinoma 2 (7.4%)
Acromegaly 5 (18.5%)
Cushing disease 0
Ganadotropinoma 0
Thyrotropinoma 0
Silent-ACTH adenoma 0
Immunohistochemical findings
Null cell adenoma (NCA) 10 (37%)
Hormonal immunopositivity 17 (63%)
GH positive 4 (15%)
PRL positive 4 (15%)
ACTH positive 3 (11%)
TSH positive 1 (4%)
FSH positive 5 (18%)
LH positive 10 (37%)
Plurihormonality 4 (15%)
Histopathological features of malignancy* 1 (4%)
Clinical observation
 after 1 year
Progression 6 (22%)
*Traditional histopathological features of malignancy, like nuclear polymorphism, presence of mitotic figures, high cellularity, cytological atypias, presence of 
necrosis might be an indicator of more aggressive behavior.
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without gonadotropinomas (3.095%, [IQR=3.195] versus 
0.45% [IQR=0.98], p=0.026) (Figure 3).
Also, the PTMA-c median was significantly higher for 
the subpopulation with gonadotropinomas than in the 
group without gonadotropinomas (3.35%, [IQR=42.86] 
versus 21.13%, [IQR=24.9], p=0.039) (Figure 4). There was 
no such difference in the case of Ki-67 (p=0.32).
PtMA-n
There was a significant correlation between PTMA-n and 
the size of the tumor (p=0.045) (shown in Figure 5). 
dIscussIon
Many studies aim to find a new biological marker that 
could be useful in the early diagnosis of pituitary ade-
nomas or pituitary cancers. So far, a marker has not 
been found that can independently predict the aggres-
sive behavior of tumors. A significant correlation 
between Ki-67 and the recurrence of tumors has been 
in comparison to the group with a tumor that did not 
progress (0.94% ± 0.32 versus 2.1% ± 0.97, p=0.046).
locAl InvAsIon
There was a statistically insignificant difference between 
studied markers and local tumor invasion and optic chi-
asm compression (in the case of PTMA-n, p=0.06; in 
PTMA-c, p=0.55). 
horMonAl ActIvIty
There was no significant difference between studied 
markers and clinical hormonal pituitary adenoma activ-
ity (FPA versus NFPA). Similarly, there was no significant 
difference between studied markers and general positive 
immunohistochemical hormonal expression (non-NCA 
versus NCA). However, in the group with gonadotropi-
noma, there was a significant difference. The PTMA-n 
median was significantly higher in the subpopulation 
with gonadotropinomas (positive immunohistochemi-
cal reaction to FSH and LH) in comparison to the group 
Table 2.  Expression of Ki-67 and PTMA in the group (n=27)
Ki-67 PTMA-c PTMA-n
frequency 21 / 27 (77.8%) 25 / 27 (92.6%) 22 / 27 (81.5%)
medium/median value [%] 1.8 / 1.4 35.6 / 27.7 1.84 / 0.67
min.-max. [%] 0 - 5.71 0 - 90.3 0 - 9.04
Correlation between Ki-67 / PTMA-c p=0.8 -
Correlation between Ki-67 / PTMA-n - p=0.009
PTMA-c: PTMA-cytoplasmatic, PTMA-n: PTMA-nuclear.
Fig. 2. Correlation between PTMA-n and Ki-67 expression
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the primary tumors, and it was also higher in NFPA. No 
correlation between Ki-67 and PTMA or between PTMA 
and local invasion was found [13]. Strong immunosta-
ining occurred not only in cell nuclei but also in the 
walls of intratumoral blood vessels; this also occurred in 
cytoplasm to a lesser degree [13].
As in our study, there was significantly higher mean 
expression of PTMA-n and PTMA-c in the group with 
gonadotropinomas.
However, our research did not confirm the role of PTMA 
as a marker of pituitary adenoma progression. In our 
study, tumor progression was defined as evidence of 
recurrence or increase of the remnant tumor in MRI/CT 
found in several studies [19,20,21]. Some studies have 
shown a significant association between PTMA-n and 
the advanced stages of head and neck tumors and have 
revealed PTMA-n to be an independent predictor of poor 
prognosis [14,17].
There have only been two studies of PTMA and pituitary 
adenoma; they were conducted by Pawlikowski et al., 
who studied the correlation between Ki-67 and PTMA 
and pituitary adenoma hormonal phenotype, prolifera-
tion, recurrence, and invasiveness [12,13]. 
According to the results of the second article and an 
analysis of 62 pituitary adenomas, the PTMA-n index 
was significantly higher in recurrent adenomas than in 
Fig. 5. Correlation between PTMA-n and size of tumor
Fig. 3.  Distribution of PTMA-n in patients with or without gonadotropinoma 
(Box plot)
Fig. 4.  Distribution of PTMA-c in patients with or without gonadotropinoma 
(Box plot)
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conclusIon
The expression of Ki-67 and PTMA was observed in the 
majority of pituitary adenomas, and PTMA-n expres-
sion correlated with Ki-67. There was a significant cor-
relation between PTMA-n and tumor size. PTMA-n and 
PTMA-c were significantly higher in gonadotropinomas 
than in other groups. However, the expression of neither 
Ki-67 nor PTMAc was related to tumor recurrence or 
local invasion. 
Due to the discrepancies between previous studies, addi-
tional research is needed to reveal the role of PTMA in 
pituitary adenomas.
after one year of observation following surgery. We did 
not divide the analyzed group into primary and recur-
rent adenomas. 
In contrast to the research of Pawlikowski, we found 
a significant correlation between Ki-67 and PTMA-n 
(p=0.009) and between PTMA-n and the size of the tumor 
(p=0.045). 
The differences between the two studies may be the 
result of the difference between the size of the analyzed 
groups (62/27 patients) and the observation time of the 
studies (1 year/5 years).
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